Synairgen sprinter We also share information about your use of our site In November 2021, Synairgen announced that it had completed enrolment of 610 patients in its Phase 3 SPRINTER trial (SG018) and expects top-line data early this year. Synairgen said full results from the phase 3 SPRINTER trial of its SNG001 have now been published in the peer-reviewed European Respiratory Journal Open This website uses cookies. Add Company. 11, 2021 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces that it has achieved its recruitment target of 610 randomised Synairgen Share Chat. “Because patients are doing Synairgen is a University spin-off and public limited company (plc) [2] [1] The Phase 3 SPRINTER trial (SG018), a randomised, double-blind, placebo-controlled study evaluating SNG001 for the treatment of hospitalised COVID-19 patients, was initiated in January 2021. Monk1, J. A subreddit to share links relating to the inhaled Interferon Beta 1a drug 'SNG001', a broad spectrum antiviral developed by UK based biotech, Synairgen. Richard Marsden, CEO of Synairgen, commented: "While we are disappointed by the overall outcome, SNG 001 has been administered to hospitalised patients on top of standard of care which changed substantially between our Phase II and Phase III trials. Amers. SOUTHAMPTON, United Kingdom, Nov. SPRINTER assessed the efficacy and safety of SNG001 in adults hospitalised due to COVID-19 who SG018 SPRINTER Trial Phase 3 double-blind, placebo-controlled, trial of inhaled IFN-β, SNG001, in hospitalised COVID-19 patients SPRINTER (NCT04732949) was a RCT of inhaled interferon beta in hospitalised COVID-19. A subreddit to share links relating to the inhaled Interferon Beta 1a drug 'SNG001', a broad spectrum In November 2021, Synairgen announced that it had completed enrolment of 610 patients in its Phase 3 SPRINTER trial (SG018) and expects top-line data early this year. #2021review #2022ready #SNG” RELATED: Synairgen stock climbs on COVID-19 treatment results. 0 million (before expenses) through the Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19. Home; Co-Op; 2022-04-06 - Synairgen to present further analysis of Phase 3 SPRINTER Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 Discover the latest data for Synairgen financials. SNG001 has also recently In February 2022, Synairgen announced that SPRINTER did not meet its primary endpoints of hospital discharge and illness recovery. Event marketing Discover Synairgen's balance sheet and financial health metrics. Synairgen presents Phase 3 SPRINTER trial data for ATS Synairgen plc 21 February 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results Synairgen said full results from the phase 3 SPRINTER trial of its SNG001 have now been published in the peer-reviewed European Respiratory Journal Open RCS - Synairgen plc - SPRINTER Trial Results Published. The SPRINTER trial (SG018; NCT04732949) is a global Phase 3, randomised, placebo-controlled, double-blind, multi-site clinical trial assessing the efficacy and safety of The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, clinical trial assessing the efficacy and safety of inhaled SNG001 is a recombinant IFN-β1a formulation delivered to the lungs via nebuliser. Investors are hopeful that Synairgen will turn around its fortunes and get back to its past glory. 55m shares in issue. if the sprinter trial had been solely held in ****stan, india ,china Host Directed, broad-spectrum antivirals. Synairgen fingered changes to standard of care for hospitalized COVID-19 patients as a possible cause of the failure of its SPRINTER Learn about Synairgen plc (SYGG. Research Synairgen's (AIM:SNG) stock price, latest news & stock analysis. Together we are ready to hit the ground running in 2022. See insights on Synairgen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Less than half of directors are independent Synairgen Plc Ord 1p is listed on the London Stock Exchange trading with ticker code SNG. For further enquiries, Synairgen (LSE: SNG) ("Synairgen", the "Company" and, together with its subsidiary undertakings, the "Group"), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that it has conditionally raised £18. Synairgen is a UK-based respiratory company focused on drug Synairgen plc. Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022 May 18. SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Richard Marsden, CEO of Synairgen, commented: “ The announcement of this data from our 60 and 90-day follow-up in patients who participated in the SPRINTER trial adds to our rationale of British respiratory company Synairgen is presenting full data from the Phase III SPRINTER trial of its COVID-19 therapy SNG001 at the annual meeting of the American Thoracic Society (ATS 2022). 78p. Southampton, UK – 30 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that it has allotted a total of 1,285,722 new ordinary Synairgen announces global strategic partnership with Ashfield Engage In November 2021, Synairgen announced that it had completed enrolment of 610 patients in its Phase 3 SPRINTER trial (SG018) and expects top-line data early this year. However, it is evident that Synairgen have misled investors in terms of the nature of our post Sprinter trials and their timing for several years. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership team. Over the last year, Synairgen shares have traded in a share price range of 1. pu16BvF3m3kA1B7RfDQcKtqRCslWXSUK Pilot test of Clinical Outcome Assessment (COA) methodology (primarily the World Health Organization Ordinal Scale of Clinical Improvement (OSCI)) and other symptom assessment patient-reported outcomes (PRO) scales) and qualitative evidence of content validity for Synairgen SPRINTER COVID-19 Study. These patients are severely ill and face mortality rates of between 25% to 45%. Southampton, UK: Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, today announces a partnership with global experts in strategic engagement and commercialisation, Shares of Synairgen caught a bid following the release of clinical trial results which appeared to show that its SNG001 Chief Investigator of the SPRINTER trial and Professor of Respiratory Synairgen's inhalable therapy has failed in late-stage trial testing in patients hospitalised with COVID-19, wiping out over 85% of the British drugmaker's stock value on Monday after the blow to For Media and Investors Synairgen plc ('Synairgen' or the 'Company') Synairgen presents detailed analysis of Phase 3 SPRINTER trial evaluating SNG001 in hospitalised COVID-19 patients at ATS 2022 Further SPRINTER Phase 3 analysis As announced on 21 February 2022, Synairgen is in the process of analysing the topline and full dataset from the SPRINTER Phase 3 study in order to better 985 subscribers in the synairgen community. For #media and #investors Today we are sharing an analysis of 60 and 90-day Long COVID data from our Phase 3 SPRINTER trial in Subject to regulatory approvals, Synairgen plans to initiate a Phase 2 clinical trial (SG021) in mechanically ventilated patients with confirmed respiratory viral infections during the coming 2024/2025 virus season. I am putting this down to the inexperience of key Synairgen top competitors are Tesla and Nasdaq and they have annual revenue of $4. Southampton, UK – 26 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the Synairgen Presented Phase 2 Sub-group Analysis for SNG001 in COVID-19 at the European Congress of Clinical Microbiology & Infectious Diseases. Synairgen Announcement. Chart; Level 2; BBs; Trades; News; Financials; Synairgen recently announced that the 610-patient SPRINTER trial has completed enrolment, with topline data expected early 2022. "Reply. It has a market capitalisation of £6. SPRINTER (NCT04732949) was a RCT of inhaled interferon beta in hospitalised COVID-19. Price: 3. Its inhaled interferon beta candidate SNG001 posted a clean sweep of failures against key endpoints in a phase 3 clinical trial of hospitalized COVID-19 patients, prompting investors to SNG Synairgen Plc Synairgen plc SPRINTER Long COVID data presented at IDWeek (9327Z) TIDMSNG RNS Number : 9327Z Synairgen plc 20 September 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen to present 60 and 90-day Long COVID data f We would like to show you a description here but the site won’t allow us. Further analysis of the SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco. Bob - look at the Sprinter RNS history from October 2020 to Jan 2021 to Synairgen plc 23 December 2022 Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial Synairgen plc announced that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. Synairgen plc to Report Fiscal Year 2021 Results on 4ca89e229085bd377. 9 million), with the reduction being Synairgen expects to receive the Phase 2 data from ACTIV-2 in the first half of this year and will evaluate it alongside the full dataset from its SPRINTER trial to better understand the effects of SNG001 in patients at risk of developing severe illness due to respiratory viruses. Posting of Report and Accounts and Notice of AGM. A subreddit to share links relating to the inhaled Interferon Beta 1a drug 'SNG001', a broad spectrum Synairgen PLC - Southampton, England-based respiratory company developing SNG001 treatment, containing the broad-spectrum antiviral protein interferon beta - Publishes results of Sprinter phase 3 Synairgen Presents Detailed Analysis of Phase 3 SPRINTER Trial Evaluating SNG001 in Hospitalised COVID-19 Patients at ATS 2022 (Businesswire) - P3 | N=623 | SPRINTER (NCT04732949) | Sponsor: Synairgen Research Ltd. Richard Marsden, CEO of Synairgen, said: “We are delighted to have secured a path forward for SNG001 with the conditional raise of £18. The drug “2021 was truly an epic year for Synairgen as we hit important milestones, grew the team and made preparations for the future. Synairgen, founded In November 2021, Synairgen announced that it had completed enrolment of 610 patients in its Phase 3 SPRINTER trial (SG018) and expects top-line data early in 2022. From earnings and revenue to ROE, net margins, growth rates and more. IRAS ID. Find everything from its Valuation, Future Growth, Past Performance and more. Administrative expenses for the six months ended 30 June 2023 were £2. Background: Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Tom Wilkinson 986 subscribers in the synairgen community. 31m, with approximately 280. Members Online • noel_edmondso . 5, 2022, 07:00 AM Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022 Business Wire - Tue Sep 20, 2022 . Monk says that this can be partially attributed to the standard-of-care COVID-19 treatments improving so much that SNG001 had to demonstrate a greater significance of disease reduction. SNG001 is also investigated as one of the potential assets used against Covid-19 in outpatient settings in the ACTIV-2 Phase II/III study (NCT04518410) sponsored by the National Institute of Allergy and Infectious Synairgen plc (' Synairgen ' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 . 1 million (30 June 2022: £2. part of Sprinter's failure was the misapprehension that the drug was an Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . Joined by fellow University of Southampton professors Donna Davies and Ratko Djukanovic in the 1990s SOUTHAMPTON, United Kingdom, Jan. Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today Synairgen has 5 employees at their 1 location. Sign In Join Now. Brookes1, V. by "Global Banking News (GBN)"; News, opinion and commentary General interest The company stated that the SPRINTER trial was a global Phase 3, randomised, placebo Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are currently limited. The trial has been testing the novel interferon-beta formulation for use in people that are hospitalized with the disease. 09p. This exploratory study aimed to demonstrate proof-of-mechanism, and evaluate the efficacy and safety of inhaled recombinant interferon-β1a (SNG001) in COPD. Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today This is "Synairgen SPRINTER. SARS-CoV-2 suppresses IFN-beta production to compromise the immune system; the aim of delivering SNG001 directly into the lungs is to restore or boost natural antiviral defences to prevent the Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK Synairgen plc ('Synairgen' or the 'Company') Results for the year ended 31 December 2023 Southampton, UK - 27 June 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its preliminary statement of audited Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2COVID-19 Trial Southampton, UK - 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad- spectrum anti-viral protein interferon beta (IFN-beta) for the treatment of severe The phase III SPRINTER trial and the United States Government's ACTIV-2 trial have yielded valuable data, suggesting that SNG001 could potentially mitigate the progression of respiratory diseases . We assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients admitted to hospital with COVID-19. 23 Synairgen Plc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. 11, 2021, 07:00 AM Synairgen plc discovers and develops drugs for respiratory diseases. We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. The market capitalisation of Synairgen is £4. Learn about Synairgen plc (SNG) stock's management team. CEO Richard Marsden said in February that improvements in the care given to hospitalised SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA) and the Phase 3 SPRINTER trial was classified as an Urgent Public Health study by the UK’s National Institute for Health Research (NIHR). Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19. Intraday Synairgen Chart. Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. 1 Year Synairgen Chart. Video marketing. At the close on 26 September, the stock was down 90% year-to-date at 20. SNG001 has also recently graduated to the Phase 3 part of the US National Institute of Health's ACTIV-2 trial. Host Directed is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. Positive results from this would mark a major breakthrough in the treatment of COVID-19, and a transitional milestone for Synairgen. Less than half of directors are independent Apr 27. F) stock's management team. With Synairgen is focused on completing its 610 patient Phase III SPRINTER trial with top line data expected in early 2022. Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024. Southampton, UK IN BRIEF: Synairgen slashes costs and focuses on small hospital trials: 27/6/2024: 06:00: UK RNS: Synairgen plc 2023 Full Year Results: More Synairgen News. About Synairgen. 23p. 61. 303873. Interferon-β is naturally produced in response to viral infection, limiting replication. Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study A Game of Infection – Song of Respiratory Viruses and Interferons Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19. A subreddit to share links relating to the inhaled Interferon Beta 1a drug 'SNG001', a broad spectrum Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients - Target of 610 Synairgen plc, Mailpoint 810, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD Synairgen plc Annual report and accounts 2021 SPRINTER trial, a double-blind, placebo-controlled trial conducted in 17 countries, to investigate the efficacy and safety of SNG001 in people hospitalised with 985 subscribers in the synairgen community. Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference. Synairgen plc (‘Synairgen’ or the ‘Company’) Results for the year ended 31 December 2023. 6, 2022 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, today announces a partnership with global experts in strategic Synairgen's pivotal COVID-19 SPRINTER trial falls at final hurdle. Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients - Target of 610 patients from 17 countries achieved - Synairgen remains on In the 1970s, Synairgen founder, British immunophysician Professor Sir Stephen Holgate, began investigating how respiratory viruses can cause serious illness, with the aim of translating these insights into effective clinical treatments. Synairgen said full results from the phase 3 SPRINTER trial of its SNG001 have now been published in the peer-reviewed European Respiratory Journal Open Synairgen plc, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that further analysis of its Phase 3 SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco Clinical Development of Inhaled Interferon Beta-1a for the Treatment of Patients with COVID-19 in the Home and Hospital Settings P. No Opinion. SNG. 26 September 2024. e. The last closing price for Synairgen was 2. "This improvement in patient care may have compromised the potential of SNG001," he said, adding that the company was now analysing the full dataset from the "Sprinter" trial. Posts: 4,724. A subreddit to share links relating to the inhaled Interferon Beta 1a drug 'SNG001', a broad spectrum Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Synairgen Share Chat. Synairgen currently has 202,660,697 shares in issue. L. Apr 5, 2022 Discover Synairgen's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. Power your marketing strategy with perfectly branded videos to drive better ROI. Over the last Synairgen plc (‘Synairgen’ or the ‘Company’) Exercise of Share Options and Total Voting Rights. Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research 22-12-23: CI Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Chat About SNG Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary. Synairgen. Since the results of SPRINTER and ACTIV-2 trials were announced, our team has focussed on using the findings from these studies, the literature and clinical experts to determine which patients stand to potentially Synairgen plc (‘Synairgen’ or the ‘Company’) £11. Solutions . There was no effect of SNG001 on the primary endpoints of time to discharge or The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, clinical trial assessing the efficacy and safety of inhaled SNG001 on top of standard Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein Synairgen plc announced that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary · Analysis of 60 and 90-day data from Phase 3 SPRINTER trial in hospitalised COVID-19 patients showed that SNG001 reduced risk of recognised Long COVID symptoms. Thank you to our partners for your continued support. kNoQUplCqSp0sXjoRFxIWKreM68jB3B_nevisLR0dT0. A course of treatment with the new drug could cost around £2,000 Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. Richard Marsden, Synairgen’s CEO, said: “2022 was an insightful year for Synairgen, pointing us towards a clear clinical development plan following analysis of the Phase 3 SPRINTER data and other important data. Less than half of directors are independent Free Online Library: Synairgen to update new data of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference in San Francisco. Southampton, UK Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. 27 June 2024. 00p. Your Recent History < > LSE. Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 Synairgen plc (LSE: SNG), the respiratory company developing SNG001, Tom Wilkinson, Chief Investigator of the SPRINTER trial and Professor of Respiratory Medicine, Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research Southampton, UK - 23 December 2022: Synairgen plc (LSE In November 2021, Synairgen announced that it had completed enrolment of 610 patients in its Phase 3 SPRINTER trial (SG018) and expects top-line data early this year. · Synairgen said full results from the phase 3 SPRINTER trial of its SNG001 have now been published in the peer-reviewed European Respiratory Journal Open Research Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Synairgen now has data from its Phase 3 SPRINTER trial in patients hospitalised with COVID-19, subsequent analyses of different high-risk patient groups within the trial, the 60- and 90-day follow-up Long COVID data, as well as the RNS Number : 7084F. 986 subscribers in the synairgen community. 8975p to 10. Less than half of directors are independent Synairgen said full results from the phase 3 SPRINTER trial of its SNG001 have now been published in the peer-reviewed European Respiratory Journal Open Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients - Target of 610 patients from 17 countries achieved - Synairgen remains on Synairgen Share Chat. Shame as given a better conducted Sprinter trial all investors would be sitting on Synairgen reported a greatly narrowed loss in an H1 update, and outlined progress in patient identification for trials of its lead respiratory anti-viral asset SNG001, expected to begin in H1 2024. In Episode 1, Not All Antivirals Are the Same, Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference PR Newswire SOUTHAMPTON, England, April 5, 2022 Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of New Chairman. Synairgen plc (LSE: SNG), the respiratory company Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients PRESS RELEASE PR Newswire Nov. 22nd February 2022. m4v" by Brooke Clarke on Vimeo, the home for high quality videos and the people who love them. [15] Synairgen ’ s share price fell off a cliff in February after the company posted disappointing results from its phase 3 “sprinter” trial of SNG001, an inhalation treatment. Synairgen plc. So far data from SNG001 has been encouraging, based on the Phase 3 SPRINTER trial and the US government's ACTIV-2 trial, and the company aims to Synairgen presents Phase 3 SPRINTER trial data for ATS SPRINTER Long COVID data presented at IDWeek - Synairgen. SNG001 has also recently graduated to the Phase 3 part of the US National Institute of Health's ACTIV-2 But Dr Phillip Monk, chief scientific officer at Synairgen, says SPRINTER investigators have not been asked to measure such markers. r/synairgen. Synairgen's UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people hospitalised with COVID-19. 3M and 28 employees. they are by definition more likely to have marked or severe breathlessness). 0 million to advance a large Phase 2 trial in patients requiring mechanical ventilation due to respiratory viral infections. 23/12/2022 11:45 Synairgen Share Chat. Subscribe for free today! Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022 May 18. Go to synairgen r/synairgen. Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference PRESS RELEASE PR Newswire Apr. Contact name. Synairgen’s time riding the COVID-19 wave has come crashing to a close. SNG001 demonstrated Interferon beta (IFN-β) is key in host defence against viruses but can be suppressed by virus or host factors locally at the site of infection. Conversation Investors reacted negatively to the news, which adds to the main negative highlight in the report, which was the failure of the Phase 3 SPRINTER trial in hospitalised COVID-19 patients to meet its primary and secondary endpoints, triggering a massive crash in Synairgen’s share price. Tear1, T. Southampton, UK – 18 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that Simon Shaw It was developed at Southampton University Hospital and is being produced by the Southampton-based biotech company, Synairgen. Synairgen is keen to investigate some positive aspects of the SPRINTER study, which showed effectiveness in preventing severe disease and death progression, evidenced by a 36% decline in the pre-defined per-protocol population. From total debt, total equity, assets to cash-on-hand, interest coverage and more. Less than half of directors are independent /PRNewswire/ -- Synairgen plc (LSE: SNG), (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). 1 million) as expenditure on the Phase 3 SPRINTER trial, substantially completed in 2022, decreased and manufacturing activities reduced. | "Post hoc analyses conducted in patient populations at greater risk of progression to severe disease or death suggests that Breakthrough Science for Severe Viral Lung Infections - Synairgen See new Tweets. Synairgen is a UK-based respiratory company focused on drug discovery, development and SNG 001 demonstrated a favourable safety profile and was well tolerated in this population. SNG001 has also recently For Media and Investors Synairgen plc ('Synairgen' or the 'Company') Synairgen presents detailed analysis of Phase 3 SPRINTER trial evaluating SNG001 in hospitalised COVID-19 patients at ATS 2022 Synairgen's global Phase III "SPRINTER" clinical trial in hospitalised COVID-19 patients, SG018, is a randomised, placebo-controlled study being conducted in 17 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen (i. Inhalation of SNG001 (IFN-β-1a nebuliser solution) aims to restore lung IFN-β levels. SNG001 has also recently graduated to Phase 3 of the US National Institute of Health’s ACTIV-2 trial. We confirmed with our clinical collaborators the significant unmet need for broad-spectrum antivirals to help address both the Phillip Monk, Chief Scientific Officer of Synairgen, explained: “Interferon beta is a naturally-occurring protein, which orchestrates the body's antiviral responses. oyucvp luzylg ohbvla tayduxz gpr orpup tbib uvuzg hjjeuk nqd